Takeda Pharmaceutical has a robust drug discovery pipeline to meet future clinical demand. Check out the upside and downside ...
Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, gastrointestinal (GI) and hematology, while pushing the Japanese company’s cell ...
A Massachusetts man who, along with his girlfriend, defrauded Takeda Pharmaceutical Co. of $2.3 million and used the money to ...
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the ...
The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...
Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug ...
Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...
Sanctuary Advisors LLC cut its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 57.9% ...
A Brockton man was sentenced for defrauding a pharmaceutical company out of $2.3 million and spending the proceeds on a ...
In honor of Rare Disease Day, the Celtics are teaming with Takeda Pharmaceuticals to raise awareness and support for the rare disease community.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback